Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITADEL
2025-522306-21-00Phase 2Authorised
- Sponsor
- University of Milano-Bicocca
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of citicoline in confusion, delirium, vascular encephalopathy (VE) and 1 more (2 arms), sponsored by University of Milano-Bicocca. Primary endpoint: Change in cognitive function by MoCA from pre-discharge to 6 months. Planned start Oct 2025; status: authorised.
02
Drugs
citicoline
03
Conditions
confusiondeliriumvascular encephalopathy (VE)hip fracture
Beyond the preview
Go deeper on 2025-522306-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522306-21-00.